We then correlated CXCL12 levels with neurodegenerative disease biomarkers, including ubiquitin carboxyl-terminal esterase L1, total tau, phosphorylated tau 181, amyloid-β, α-synuclein and NEFL (Fig. S8E). Here, MAPT is linked to neurodegenerative disease.